This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday – Eupraxia Pharmaceuticals (NASDAQ:EPRX), Braze (NASDAQ:BRZE)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Canaccord Genuity analyst Edward Nash initiated coverage on Sagimet Biosciences Inc. SGMT with a Buy rating and announced a price target of $28. Sagimet Biosciences shares closed at $9.59 on Wednesday. See how other analysts view this stock.
Citigroup analyst Yigal Nochomovitz initiated coverage on Sarepta Therapeutics, Inc. SRPT with a Sell rating and announced a price target of $7. Sarepta Therapeutics shares closed at $13.32 on Wednesday. See how other analysts view this stock.
Cantor Fitzgerald analyst Kristen Kluska initiated coverage on Eupraxia Pharmaceuticals Inc. EPRX with an Overweight rating and announced a price target of $11. Eupraxia Pharmaceuticals shares closed at $5.06 on Wednesday. See how other analysts view this stock.
B of A Securities analyst Ronald Epstein initiated coverage on Elbit Systems Ltd. ESLT with a Buy rating and announced a price target of $500. Elbit Systems shares closed at $445.97 on Wednesday. See how other analysts view this stock.
Mizuho analyst Siti Panigrahi initiated coverage on Braze, Inc. BRZE with an Outperform rating and announced a price target of $40. Braze shares closed at $28.44 on Wednesday. See how other analysts view this stock.